Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 3/20 | 0.60 |
| ▸ | CTSL | P07711 | 2/20 | 0.60 |
| ▸ | EGFR | P00533 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940559 | 0.86 | CTSL (0.63) | CTSL | |
| SCHEMBL8428302 | 0.81 | CTSL (0.55) | CTSKCTSLEGFR | |
| SCHEMBL8428303 | 0.81 | CTSL (0.55) | CTSKCTSLEGFR | |
| SCHEMBL27076998 | 0.80 | CTSK (0.64) | CTSKCTSLEGFR | |
| SCHEMBL25917253 | 0.79 | CTSK (0.53) | CTSKCTSLEGFR | |
| SCHEMBL942179 | 0.78 | METTL3 (0.66) | CTSKCTSL | |
| SCHEMBL8341601 | 0.77 | CTSK (0.51) | CTSKCTSLEGFR | |
| SCHEMBL27614853 | 0.75 | EGFR (0.47) | CTSLEGFR | |
| SCHEMBL15366757 | 0.75 | CTSL (1.00) | CTSKCTSL | |
| SCHEMBL8341604 | 0.75 | CTSK (0.49) | CTSKCTSLEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050113283-A1 | Methods of treating conditions associated with an EDG-4 receptor | MANIV ENERGY CAPITAL | 2005-05-26 | — | — | US | disclosed |
| EP-1513522-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | SRI INTERNATIONAL (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003062392-A2 | METHODS OF TREATING CONDITIONS ASSOCIATED WITH AN EDG RECEPTOR | CERETEK LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113283-A1 | Methods of treating conditions associated with an EDG-4 receptor | EDNRA, EDNRB, ESRRG | CTSK 1286/4885CTSL 1097/4885EGFR 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.